Drug Trial Radar · NCT07732010
TRYPTYR as a Treatment for Patients With Dry Eye Disease (DED)
Last checked: Nov 20, 2026Latest source record: Jul 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
50
Planned (sponsor's estimate)
Start
Jul 6, 2026
Primary completion
Apr 20, 2027
Study completion May 25, 2027
Sponsor
- Lead sponsor
- NYU Langone HealthAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jul 28, 2026
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this research study is to determine the effectiveness of TRYPTYR as a treatment for Dry Eye Disease. The primary efficacy variable is change from baseline in the Ocular Surface Disease Index (OSDI) at week 2. The co-primary efficacy variables are change from baseline in the National Eye Institute (NEI) scale of the cornea and NEI scale of the conjunctiva at 1 month (the third visit).
Conditions
- Dry Eye Disease (DED)
Interventions
TRYPTYR (Acoltremon ophthalmic solution 0.003%)Drug
TRYPTYR will be administered one drop in each eye twice daily (once every 12 hours) for 30 days.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in ocular surface disease index (OSDI) ScoreTime frame: Baseline, Week 2
- Change in National Eye Institute (NEI) scale of the corneaTime frame: Baseline, 1 Month
- Change in NEI scale of the conjunctivaTime frame: Baseline, 1 Month
Locations
1 site in 1 country. Site status is shown where the registry gives one.
NYU Langone Health
New York, New York · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.